Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Caitlin E. Cox

December 11, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

Todd Neale

November 20, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Shelley Wood

October 25, 2019

News Daily News

Elderly Women Worse Off Than Men Before and After Acute MI

Yael L. Maxwell

October 22, 2019

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

Michael O'Riordan

September 24, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Daily News

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Todd Neale

August 23, 2019

News Daily News

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Shelley Wood

August 05, 2019

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Shelley Wood

July 23, 2019

News Daily News

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Michael O'Riordan

July 03, 2019

News Daily News

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

Todd Neale

June 26, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Conference News EAS 2019

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

Michael O'Riordan

May 28, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

Advertisement

FDA Approves Icosapent Ethyl for Reducing CVD Events

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Elderly Women Worse Off Than Men Before and After Acute MI

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Analysis Hints at Survival Benefit With Revascularization in Stable Patients With Myocardial Ischemia

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

PolyIran: Polypill Prevents Major Cardiovascular Events Over 5 Years

Best Strategy Questioned for NSTE ACS Patients With Prior CABG

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

Field in Flux: What’s the Best Antithrombotic Strategy for A-fib Patients Undergoing PCI?

Which ASCVD Patients Will Benefit Most From Rivaroxaban Plus Aspirin? Some Clues

New Clarity on Patients at High Risk for Bleeding After PCI

Clear CVD Risk Reduction With PCSK9 Inhibitors, but No Mortality Effect: Meta-analysis

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content